• 1
    Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983.
  • 2
    Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
  • 3
    Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005; 31: 217-233.
  • 4
    Beldi G, Enjyoji K, Wu Y, Miller L, Banz Y, Sun X, et al. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. Front Biosci 2008; 13: 2588-2603.
  • 5
    Thevananther S, Sun H, Li D, Arjunan V, Awad SS, Wyllie S, et al. Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes. HEPATOLOGY 2004; 39: 393-402.
  • 6
    Jacques-Silva MC, Bernardi A, Rodnight R, Lenz G. ERK, PKC and PI3K/Akt pathways mediate extracellular ATP and adenosine-induced proliferation of U138-MG human glioma cell line. Oncology 2004; 67: 450-459.
  • 7
    Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE, et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010; 139: 1030-1040.
  • 8
    Jackson SW, Hoshi T, Wu Y, Sun X, Enjyoji K, Cszimadia E, et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol 2007; 171: 1395-1404.
  • 9
    Feng l, Sun X, Csizmadia E, Han l, Murakami T, Wang X, et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 2011; 13: 206-216.
  • 10
    Enjyoji K, Kotani K, Thukral C, Blumel B, Sun X, Wu Y, et al. Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008; 57: 2311-2320.
  • 11
    Beldi G, Wu Y, Sun X, Imai M, Enjyoji K, Csizmadia E, et al. Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. Gastroenterology 2008; 135: 1751-1760.
  • 12
    Lebel M, de Souza-Pinto NC, Bohr VA. Metabolism, genomics, and DNA repair in the mouse aging liver. Curr Gerontol Geriatr Res 2011; 2011: 859415.
  • 13
    Sikder H, Huso DL, Zhang H, Wang B, Ryu B, Hwang ST, et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003; 4: 291-299.
  • 14
    Pikarsky E, Ben-Neriah Y. NF-kappaB inhibition: a double-edged sword in cancer? Eur J Cancer 2006; 42: 779-784.
  • 15
    Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS 2nd, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999; 5: 1010-1017.
  • 16
    Koen H, Pugh TD, Goldfarb S. Hepatocarcinogenesis in the mouse. Combined morphologic-stereologic studies. Am J Pathol 1983; 112: 89-100.
  • 17
    Wu Y, Sun X, Kaczmarek E, Dwyer KM, Bianchi E, Usheva A, et al. RanBPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem J 2006; 396: 23-30.
  • 18
    Beldi G, Wu Y, Banz Y, Nowak M, Miller L, Enjyoji K, et al. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. HEPATOLOGY 2008; 48: 841-852.
  • 19
    Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006; 314: 1792-1795.
  • 20
    Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer (HLRCC). Mol Cancer Ther. 2009; 8: 626-635.
  • 21
    Seth P, Grant A, Tang J, Vinogradov E, Wang X, Lenkinski R, et al. On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia 2011; 13: 60-71.
  • 22
    Becker FF. Morphological classification of mouse liver tumors based on biological characteristics. Cancer Res 1982; 42: 3918-3923.
  • 23
    Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726-734.
  • 24
    Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
  • 25
    Dixon CJ, White PJ, Hall JF, Kingston S, Boarder MR. Regulation of human hepatocytes by P2Y receptors: control of glycogen phosphorylase, Ca2+, and mitogen-activated protein kinases. J Pharmacol Exp Ther 2005; 313: 1305-1313.
  • 26
    Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007; 450: 736-740.
  • 27
    Bjornsti M, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
  • 28
    Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
  • 29
    Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064.
  • 30
    Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-967.
  • 31
    Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479: 547-551.
  • 32
    Beldi G, Banz Y, Kroemer A, Sun X, Wu Y, Graubardt N, et al. Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice. HEPATOLOGY 2010; 51: 1702-1711.
  • 33
    Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW, et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010; 143: 711-724.
  • 34
    Read R, Hansen G, Kramer J, Finch R, Li L, Vogel P. Ectonucleoside triphosphate diphosphohydrolase type 5 (Entpd5)-deficient mice develop progressive hepatopathy, hepatocellular tumors, and spermatogenic arrest. Vet Pathol 2009; 46: 491-504.